What To Expect After The Failed AbbVie Drug Sales (NYSE:ABBV)

On April 27, 2023, AbbVie (NYSE:ABBV) released its Q1 2023 financial results. In recent quarters, sales of the company's products have shown mixed dynamics, which led to falling short of Wall Street analysts' expectations. So, AbbVie's revenue amounted to $12,225 million in the first three months…#abbvie #richardgonzalez #humira #tnf #amjevita #amgen #amgn #fda #boehringeringelheim #skyriziandrinvoq

Source: Reuters: Health - April 30, 2023 Category: Consumer Health News Source Type: news